HomeBIIB34 • BVMF
add
Biogen Inc BDR
Previous close
R$134.16
Year range
R$110.07 - R$175.78
Market cap
21.98B USD
Avg Volume
13.00
P/E ratio
-
Dividend yield
-
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 2.65B | 7.33% |
Operating expense | 783.70M | 12.02% |
Net income | 634.80M | 8.77% |
Net profit margin | 24.00 | 1.35% |
Earnings per share | 5.47 | 3.60% |
EBITDA | 1.11B | 14.61% |
Effective tax rate | 14.68% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.76B | 44.52% |
Total assets | 28.33B | 5.69% |
Total liabilities | 10.70B | -2.00% |
Total equity | 17.63B | — |
Shares outstanding | 146.61M | — |
Price to book | 1.12 | — |
Return on assets | 8.12% | — |
Return on capital | 9.57% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | 634.80M | 8.77% |
Cash from operations | 160.90M | -74.29% |
Cash from investing | -57.00M | -112.22% |
Cash from financing | -11.70M | 95.23% |
Net change in cash | 160.50M | -80.77% |
Free cash flow | 223.68M | -83.73% |
About
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Founded
1978
Headquarters
Website
Employees
7,605
